In vitro diagnostics account for only about 2% of total healthcare spending yet influence over 66% of clinical decision-making

More than 75% of the 7 lakh annual cancer deaths in India can be prevented with early screening and diagnosis

Remote monitoring can reduce Hospitalisations and deaths in heart failure patients by 29% and 20% respectively

Studies have shown that India’s health system has a persistent challenge of limited resources – including cost of care, accessible quality care, trained professionals, and lag in uptake of effective technology solutions. Limited personnel and infrastructure constraints cause long turnaround times for diagnosis and initiation of treatment contributing to the rising disease burden, out of pocket expenditures and worsening health conditions. The window for early interventions is missed, which is critical for prevention and management of most of the chronic illnesses.


Pfizer INDovation: NIPER-A Edition, with Department of Pharmaceuticals, NITI Aayog and Social Alpha as anchor partners is designed to support start-ups building high-quality affordable diagnostics.

Focus Areas

Who Should Apply

The program aims to support the progression of six healthtech start-ups (with a working proof of concept demonstrated) that are building innovative solutions to make high-quality diagnostics accessible.

Program Offerings

The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring. The start-ups will receive a grant amount of up to INR 25 lakhs and acceleration support from Social Alpha and NIPER Ahmedabad towards:
Assistance in Product Development: Access to NIPER Ahmedabad's prototyping labs/infrastructure, funds, and technical mentorship
Advisory for Design for Manufacturing: Guidance on optimising the product design by NIPER Ahmedabad’s technical experts
Tech Transfer Support from NIPER Ahmedabad: Explore collaboration opportunities for tech transfer with academia etc. through NIPER Ahmedabad's ecosystem
Advisory on Regulatory Roadmap Planning: Guidance from Social Alpha to align various regulatory and quality documents in line with statutory and international standards requirements
Pre-Clinical Studies with Partner Hospitals: Access to Social Alpha’s ecosystem for demonstration of safety and working of the solution in lab-settings (controlled and non-interventional)
Customer Discovery and Market Identification: Engagement with stakeholders (Tertiary care, Community Health Organisations, NGOs) part of Social Alpha’s network to validate problem statements, clinical fitment, and user experience

Important Dates

  • Applications Open

    February 27th, 2024
  • Deadline for Applications

    April 17th, 2024
  • Evaluation of Applications

    Mid May, 2024
  • Jury Round

    End of May, 2024
  • Announcement of Winners

    First week of June, 2024
  • Induction and Launch of the Accelerator

    Mid June, 2024
  • Incubation for 12 months

    July 2024 to June 2025

Our Partners

frequently asked questions
Terms and Conditions

For any assistance needed in filling the application form, please reach out to us at